Arcellx (ACLX) Total Non-Current Liabilities (2021 - 2025)
Arcellx's (ACLX) quarterly Total Non-Current Liabilities came in at $201.6 million in Q4 2025, down 18.67% year-on-year from $247.9 million in Q4 2024, and down 6.28% quarter-over-quarter from $215.1 million in Q3 2025.
Arcellx (ACLX) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Arcellx's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $201.6 million for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 18.67% year-over-year to $201.6 million in Q4 2025; TTM through Dec 2025 was $201.6 million, a 18.67% decrease from a year earlier, with the FY2025 full-year figure at $201.6 million, down 18.67% from the prior year.
- Total Non-Current Liabilities declined to $201.6 million in Q4 2025 per ACLX's latest filing, from $215.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $267.7 million in Q1 2024 and bottomed at $16.7 million in Q4 2021.
- The 4-year median for Total Non-Current Liabilities is $226.9 million (2025), against an average of $179.3 million.
- Biggest YoY gain for Total Non-Current Liabilities was 2.32% in 2025; the steepest drop was 19.38% in 2025.
- Year by year, Total Non-Current Liabilities stood at $16.7 million in 2021, then surged by 204.22% to $50.9 million in 2022, then soared by 386.86% to $247.9 million in 2024, then declined by 18.67% to $201.6 million in 2025.
- Per Business Quant, the three latest ACLX Total Non-Current Liabilities figures stand at $201.6 million (Q4 2025), $215.1 million (Q3 2025), and $226.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 201.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 201.64 Mn |
| Sep 30, 2025 | 215.14 Mn |
| Jun 30, 2025 | 226.86 Mn |
| Mar 31, 2025 | 227.74 Mn |
| Dec 31, 2024 | 247.94 Mn |
| Sep 30, 2024 | 266.84 Mn |
| Jun 30, 2024 | 232.24 Mn |
| Mar 31, 2024 | 267.65 Mn |
| Jun 30, 2022 | 50.93 Mn |
| Mar 31, 2022 | 18.90 Mn |
| Dec 31, 2021 | 16.74 Mn |